Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 13Recurrence 9Neoplasms 8Colorectal Neoplasms 8Pancreatic Neoplasms 7Leukemia, Myeloid, Acute 7Hematologic Neoplasms 7Carcinoma, Hepatocellular 7Lymphoma, B-Cell 6Sarcoma 5Prostatic Neoplasms 5Breast Neoplasms 5Neoplasms, Plasma Cell 4Myasthenia Gravis 4Lymphoma 4Lung Neoplasms 4Glioblastoma 4Burkitt Lymphoma 4Brain Neoplasms 4Advanced Solid Tumors 4Stomach Neoplasms 3Solid Tumor 3Ovarian Neoplasms 3Melanoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Head and Neck Neoplasms 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2

Interventions

tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Not yet recruiting × mCRPC × Clear all
NCT07389187 2026-02-05

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Shanghai Changzheng Hospital

Phase EARLY_PHASE1 Not yet recruiting
10 enrolled

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡